Picture of Oncimmune Holdings logo

ONC Oncimmune Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

REG - Oncimmune Hldgs PLC - Contract signed with Verily Life Sciences

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220228:nRSb9424Ca&default-theme=true

RNS Number : 9424C  Oncimmune Holdings PLC  28 February 2022

28 February 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Contract signed with Verily Life Sciences, an Alphabet company, to profile
autoantibodies for long COVID-19

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces the signing of a new commercial contract with Verily
Life Sciences LLC ("Verily"), an Alphabet company (parent company to Google),
focusing on the autoantibody profiling of patients who have had the COVID-19
infection and have gone on to develop long lasting symptoms lasting more than
four weeks ("Long COVID" also known as post-acute sequelae SARS-CoV-2
infection ("PASC")).

 

Under the terms of this new contract, Oncimmune will utilise its recently
validated infectious disease panel of biomarkers, developed under the IMmunity
Profiling of pAtients with COVID-19 for Therapy and Triage ("IMPACTT")
programme, to evaluate whether autoantibodies, which are present early in the
COVID-19 infection, are associated with the development of Long COVID.
Furthermore, the Company's infectious disease panel will also be used to
assess whether these autoantibodies remain elevated in Long COVID patients
during their period of recovery.

 

Should this initial discovery phase prove successful, both Oncimmune and
Verily have retained the rights to commercialise the resultant intellectual
property, including the filing of patent applications for the development of a
companion diagnostic.

 

Dr Adam M Hill, CEO of Oncimmune said: "The real impact on society of Long
COVID is only beginning to be understood. Oncimmune is a leader in infectious
disease serological antibody profiling, and therefore this partnership with
Verily, utilising Oncimmune's validated infectious disease panel, will seek to
identify autoantibodies which are indicators for Long COVID. It is yet another
exemplar of Oncimmune's leading position in autoimmune profiling.

 

"As is typical with Oncimmune's contracts, there is potential for the initial
discovery work in autoantibodies to progress onto the identification of
intellectual property rights, and to the development of viable commercial
companion diagnostic devices."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organisations to optimise drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

About Verily

 

Verily is a subsidiary of Alphabet (parent company of Google), focused on life
sciences and healthcare. Verily's mission is to make the world's health data
useful so that people enjoy healthier lives. Verily develops tools and devices
to collect, organize and activate health data, and create interventions to
prevent and manage disease. Verily partners with leading life sciences,
medical device, and government organizations, using deep hardware, software,
scientific, and healthcare expertise to enable faster development, meaningful
advances, and deployment at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUBRKRUVUUUAR

Recent news on Oncimmune Holdings

See all news